FDA pauses updates on food-borne outbreak probes as health agencies regroup on communications
The Trump administration's "short pause" on communications, expected to end on Feb. 1, has affected FDA updates on food ...
Hosted on MSN18m
FDA approves drug application for Lupin’s heart failure therapy
The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and ...
The FDA has officially banned Red No. 3. Here are some products that contain the cancer-causing dye
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...
Rolling Out9h
FDA unveils 8 critical safety measures for berry industry
FDA introduces comprehensive safety measures targeting norovirus and hepatitis A in fresh and frozen berries, addressing ...
STAT22h
FDA purges material on clinical trial diversity from its site, showing stakes of Trump DEI ban
Following the Trump administration's DEI ban, the FDA's move to scrub webpages has ensnared many pages focused on ensuring ...
FDA spars with Waco company over ‘unapproved’ and ‘unlicensed’ human amniotic products
Federal regulators have warned a Waco company that its human amniotic products are “unlicensed” and “unapproved,” and that ...
FDA releases update on chicken broth recall at Ga. Walmarts
The Food and Drug Administration has released an update on a recall for chicken broth sold at Georgia Walmarts.
Dip Recall Update as FDA Sets Risk Class
The spinach artichoke dip mix was recalled due to it having been underprocessed, the Food and Drug Administration said.
Why is the FDA slow to ban food additives?
The dye is a "color additive made from petroleum," which "could previously be used in foods in small amounts as approved by ...
Trump Administration Orders a Temporary Freeze on Food and Health Agency Communications
Dr. Dorothy Fink, the acting secretary for the Department of Health and Human Services under President Donald Trump, has ...
FDA and EMA review Biogen's higher dose SMA drug
CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...